ELOX
Eloxx Pharmaceuticals, Inc.
$10.95
-0.61 (-5.28%)
At close · Jul 7
Market Cap
$94.60M
Shares
7,573,935
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
-100%
FY2025
Net Income
-$6M
-90.7%
FY2025
Operating Margin
-38.81%
FY2024
Diluted EPS
-$5.34
+42%
FY2025
Operating Cash Flow
-$6.33M
-34.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $0 | $6.36M | $0 | — | — | — | — | — | — | $182.23K | $182.23K | $182.23K | — | $1.79M | |
| — | $3.06M | $3.58M | $8.6M | $23.73M | $22.9M | $14.59M | $25.84M | $20.49M | $16.4M | $2.18M | $4.57M | $3.34M | $23.32M | $21.24M | |
| — | $3.38M | $5.25M | $8.69M | $10.69M | $20.45M | $14.85M | $24.71M | $26.48M | $3.99M | $1.61M | $3.17M | $3.68M | $34.11M | $31.61M | |
| — | — | — | — | — | — | — | — | — | — | $24.98K | $24.98K | $331.38K | $1.21M | $921.5K | |
| — | — | — | — | — | — | — | — | — | $44.08K | $93.39K | $177.07K | $349.66K | $1.39M | $1.1M | |
| — | — | — | — | — | $1.89M | $1.89M | — | — | — | — | — | — | — | — | |
| — | $6.44M | $8.83M | $17.29M | $34.42M | $66.02M | $33.46M | $50.56M | $47.57M | $20.39M | — | — | — | — | — | |
| $627.45K | — | — | — | — | — | — | — | — | $4.59M | $11.27M | $18.15M | $9.25M | $59.41M | $52.85M | |
| — | -$6.44M | -$2.47M | -$17.29M | -$34.42M | -$66.02M | -$33.46M | -$50.56M | -$47.57M | -$20.39M | -$11.19M | -$18.08M | -$9.15M | -$57.62M | -$51.06M | |
| — | — | -38.81% | — | — | — | — | — | — | — | -6143.36% | -9919.79% | -5019.95% | — | -2852.53% | |
| — | — | — | — | — | — | — | — | — | -$20.35M | -$11.1M | -$17.9M | -$8.8M | -$56.23M | -$49.96M | |
| — | -$27K | $53K | -$31K | -$1.65M | -$709K | -$1.12M | -$319K | $502K | — | — | — | — | — | $205.39K | |
| — | -$6M | -$3.14M | -$17.05M | -$36.07M | -$66.73M | -$34.58M | -$50.87M | -$47.06M | -$21.17M | -$8.95M | — | — | — | — | |
| — | $0 | — | — | $0 | $0 | $0 | $0 | $122K | -$1.04M | -$680K | — | — | — | — | |
| — | -$6M | -$3.14M | -$17.05M | -$36.07M | -$66.73M | -$34.58M | -$50.87M | -$47.19M | -$21.21M | -$8.27M | -$18.06M | -$9.23M | -$63.06M | -$56.94M | |
| — | — | -49.43% | — | — | — | — | — | — | — | -4537.11% | -9912.68% | -5062.44% | — | -3180.82% | |
| -$1.38M | — | — | — | — | — | — | — | — | -$6.19M | -$8.45M | -$18.9M | -$13.85M | -$74.43M | -$67.44M | |
| — | — | — | — | — | -$66.73M | -$34.6M | -$50.86M | — | — | -$8.45M | -$18.9M | -$13.85M | -$74.43M | — | |
| USD/shares | — | -$5.34 | -$9.20 | -$72.98 | -$16.65 | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$5.34 | -$9.20 | -$72.98 | -$16.65 | — | — | — | — | — | — | — | — | — | — |
| shares | — | 1.12M | 341.71K | 233.67K | 2.17M | 69.96M | 40.12M | 38.06M | 32.44M | 4.98M | 20.32M | 14.42M | 5.48M | 136.64M | 85.7M |
| shares | — | 1.12M | 341.71K | 233.67K | 2.17M | 69.96M | 40.12M | 38.06M | 32.44M | 4.98M | 20.32M | 14.42M | 5.48M | 136.64M | 85.7M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2017–FY2019: $0 in dividends.